Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.62 |
| ▸ | RAB9A | P51151 | 8/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24039004 | 1.00 | NPC1 (0.62) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL24038659 | 0.88 | TP53 (0.54) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL30517434 | 0.88 | TP53 (0.54) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL24039014 | 0.86 | BRD4 (0.50) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL30517468 | 0.86 | MKNK1 (0.47) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL24038875 | 0.86 | MKNK1 (0.47) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL30517447 | 0.86 | BRD4 (0.50) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL30517467 | 0.85 | CYP1A2 (0.56) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL24038657 | 0.85 | CYP1A2 (0.56) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL31256751 | 0.83 | CHRNB2 (0.57) | NPC1RAB9AMAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4473968-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4149620-B1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS INC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, IL1B, IL1RN | NPC1 3706/4885RAB9A 2738/4885MAPT 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.